Home › Trials › NCT06249828
Clinical trial No longer in our active list Interventional Ages 50 to 65

Evaluating MegaCarti® for knee cartilage defects

Official title: A Clinical Trial to Evaluate the Efficacy and Safety of Cartilage Regeneration in the Use of MegaCarti^® in Patients with Knee Joint Cartilage Injury: Multicenter, Independent Evaluator-subject Blinded, Microfracture-comparative, Randomized Clinical Study

Run by L&C Bio · NCT06249828 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if adding MegaCarti® to a standard knee treatment can help people aged 50 to 65 with knee cartilage defects recover better.

Quick facts

Study typeInterventional
Ages50 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorL&C Bio
Industry-sponsored
Locations6 sites (Gyeonggi-do and 5 other locations)
Trial IDNCT06249828 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 50 to 65 with localized full-thickness cartilage defects in the knee joint, specifically ICRS Grade III or IV.

Probably not a fit

Patients with autoimmune diseases or those who have had recent cartilage defect treatments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on subjects aged 50 to 65 years who have knee cartilage defects. Participants will undergo a microfracture treatment followed by the application of MegaCarti®, a decellularized allogeneic cartilage designed to enhance cartilage regeneration. The efficacy of this approach will be assessed by comparing outcomes with a control group receiving only microfracture treatment, using MOCART evaluation and biopsy to measure cartilage regeneration at 48 weeks post-treatment.

Why it matters

Potential benefit: If successful, this treatment could significantly improve cartilage regeneration in patients with knee defects, potentially alleviating pain and restoring function.

How similar studies have gone: While the use of decellularized cartilage is a growing area of interest, this specific application of MegaCarti® in conjunction with microfracture is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. 50 years to 65 yaers
2. After receiving a detailed explanation of this clinical trial and fully understanding it, the subject or legal representative voluntarily decides to participate in the clinical trial and sign the consent form
3. Subjects with localized full-thickness cartilage defects in the knee joint, International Cartilage Repair Society(ICRS) Grade III or IV
4. Subjects whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms
5. knee cartilage defect size :1.5cm\^2 to 10cm\^2

Exclusion Criteria:

1. Patients who have autoimmune diseases (Ex. Rheumatoid arthritis)
2. When screening, Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (However, arthroscopy for diagnostic purposes is possible. Additionally, it is possible if hightibial osteotomy (HTO) has been performed in advance or is scheduled)
3. When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 1 month
4. When screening, Patients who took oral steroid within 2 weeks
5. Patients who can't take MRI scan
6. BMI index : 30kg/m\^2 or over
7. Patients who have gout or gout history in the knee
8. Women who are pregnant or breast-feeding, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception.
9. Patients with risk factor for bleeding
10. Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial

Where it's running

  • Chung-Ang University Gwangmyeong Hospital
    Gyeonggi-do, Korea, Republic of     Recruiting
  • Ajou University Medical Center
    Gyeonggi-do, Korea, Republic of     Recruiting
  • Catholic Kwandong University International St.Mary's Hospital
    Incheon, Korea, Republic of     Recruiting
  • Konkuk University Medical Center
    Seoul, Korea, Republic of     Recruiting
  • Yonsei University Health System, Gangnam Severance Hospital
    Seoul, Korea, Republic of     Recruiting
  • Yonsei Sarang Hospital
    Seoul, Korea, Republic of     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Osteoarthritis, Knee 66
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.